Table 2 Prevalent users characteristics at inclusion and during the study follow-up, by molecule.

Effective

20,254

31,038

53,381

Female

10,306 (51)

17,363 (56)

26,738 (50)

Age at inclusion (years)

–

–

–

Mean (SD)

45 (15.3)

53.3 (14.5)

46.7 (15.2)

18–29

3753 (19)

1716 (6)

8039 (15)

30–39

4149 (20)

3984 (13)

10,654 (20)

40–49

4634 (23)

6665 (21)

11,995 (22)

50–59

3874 (19)

7771 (25)

11,120 (21)

60–69

2569 (13)

6725 (22)

7459 (14)

70 +

1275 (6)

4177 (13)

4114 (8)

Pathology

–

–

–

Gastro-enterology

–

–

–

Crohn's Disease

8507 (42)

0 (0)

17,221 (32)

Ulcerative colitis

2784 (14)

0 (0)

5008 (9)

Rheumatology

–

–

–

Rheumatoid arthritis

2032 (10)

12,822 (41)

7366 (14)

Ankylosing spondylitis

4825 (24)

11,191 (36)

13,247 (25)

Psoriatic arthritis

733 (4)

2258 (7)

2433 (5)

Dermatology

–

–

–

Psoriasis

1076 (5)

3282 (11)

5084 (10)

Hidradenitis Suppurativa

0 (0)

0 (0)

210 (0)

Ophtalmology

–

–

–

Uveitis

0 (0)

0 (0)

536 (1)

Undetermined

297 (1)

1485 (5)

2276 (4)

Follow-up duration, mean (SD)

4.3 (2.6)

3.6 (2.1)

2.3 (1)

Follow-up duration, median (IQR)

5.3 (1.6–6.7)

5.1 (1.5–5.4)

3 (1.6–3)

Number of dispensings, mean (SD)

27.7 (18.5)

32.9 (22.6)

23.6 (13.4)

Discontinuation, molecule switch or death

11,506 (57)

16,533 (53)

20,449 (38)

Transitions

9417 (46)

5907 (19)

9285 (17)

Time to switch, median (IQR)

3.1 (2.3–3.7)

2.9 (2.2–3.6)

1.1 (0.7–1.7)

Retransitions

2054 (10)

2183 (7)

3055 (6)

Time to switch, median (IQR)

3.5 (2.4–4.7)

3.5 (2.7–4.2)

1.5 (1.1–2.1)

Biotransitions

1895 (9)

161 (1)

541 (1)

Time to switch, median (IQR)

5 (3.3–5.5)

3.7 (3.1–4.6)

1.7 (1.2–2.3)